Evidence map›Paper›PMID 40210847›Full record

ArticleNature communications2025

The Spatial Transcriptional Activity of Hepatic TCF7L2 Regulates Zonated Metabolic Pathways that Contribute to Liver Fibrosis.

Iriscilla Ayala, Skanda K Hebbale, Juho Mononen, Madelaine C Brearley-Sholto, Christopher E Shannon, Ivan Valdez, Marcel Fourcaudot, Terry M Bakewell, Anna Zagorska, Giovanna Romero and 9 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Differential Wnt/β-catenin signaling via TCF7L2/LEF1 binding specificity shapes cellular and tumor phenotypes.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Iriscilla AyalaDiabetes Division, Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.ORCID http://orcid.org/0000-0003-3374-9424
Skanda K HebbaleDiabetes Division, Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.
Juho MononenInstitute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio, Finland.ORCID http://orcid.org/0000-0002-9395-3841
Madelaine C Brearley-SholtoDepartment of Cardiology, School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-7306-9242
Christopher E ShannonDiabetes Division, Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.ORCID http://orcid.org/0000-0003-0240-0609
Ivan ValdezDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Marcel FourcaudotDiabetes Division, Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.
Terry M BakewellDiabetes Division, Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.
Anna ZagorskaGilead Sciences, Foster City, CA, USA.ORCID http://orcid.org/0009-0009-3641-7936
Giovanna RomeroDiabetes Division, Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.
Mara AsmisDiabetes Division, Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.
Fatima A MusaDiabetes Division, Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.
Jonah T SilyDiabetes Division, Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.
Annie A SmelterDiabetes Division, Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.ORCID http://orcid.org/0009-0003-9586-6228
Edgar A HinostrozaDiabetes Division, Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.
Leandro C Freitas LimaDiabetes Division, Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.ORCID http://orcid.org/0000-0001-9550-6095
Thomas Q de Aguiar VallimDepartment of Cardiology, School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-7642-5046
Sami HeikkinenInstitute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio, Finland.ORCID http://orcid.org/0000-0002-6083-2402
Luke NortonDiabetes Division, Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA. nortonl@uthscsa.edu.ORCID http://orcid.org/0000-0002-0231-5722

Funding

ATP Binding Cassette Transporters in Health and DiseaseR01DK128952 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TARLING, ELIZABETH JOANNA, VALLIM, THOMAS A · 2021 to 2024
$2.4M
The Regulation of Hepatic Metabolic Zonation by the Diabetes Gene TCF7L2R01DK128247 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Luke Norton · 2022 to 2026
$2.3M
South Texas Medical Scientist Training Program (STX-MSTP)T32GM145432 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Jose E Cavazos, Ratna K Vadlamudi · 2023 to 2026
$2.3M
Bile acid-mediated control of lipid absorption and fatty liver diseaseR01DK138340 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Thomas A Vallim · 2024 to 2026
$1.9M
NRSA Training Core (TL1)TL1TR002647 · NCATS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CHUN, YONG-HEE PATRICIA, FREI, CHRISTOPHER R. · 2018 to 2022
$1.8M
CTSA Postdoctoral T32 at The University of Texas Health Science Center at San AntonioT32TR004544 · NCATS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Yong-Hee Patricia Chun, Christopher R. Frei · 2023 to 2026
$1.1M
NCATS NIH HHS T32 TR004544NCATS NIH HHS TL1 TR002647NIDDK NIH HHS R01 DK128247NIDDK NIH HHS R01 DK128952NIDDK NIH HHS R01 DK138340NIGMS NIH HHS T32 GM145432U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) R01DK128247U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) R01DK128952
6 · The paper itself

Abstract

The molecular mechanisms regulating the zonal distribution of metabolism in liver are incompletely understood. Here we use single nuclei genomics techniques to examine the spatial transcriptional function of transcription factor 7-like 2 (TCF7L2) in mouse liver, and determine the consequences of TCF7L2 transcriptional inactivation on the metabolic architecture of the liver and the function of zonated metabolic pathways. We report that while Tcf7l2 mRNA expression is ubiquitous across the liver lobule, accessibility of the consensus TCF/LEF DNA binding motif is restricted to pericentral (PC) hepatocytes in zone 3. In mice expressing functionally inactive TCF7L2 in liver, PC hepatocyte-specific gene expression is absent, which we demonstrate promotes hepatic cholesterol accumulation, impaired bile acid synthesis, disruption to glutamine/glutamate homeostasis and pronounced dietary-induced hepatic fibrosis. In summary, TCF7L2 is a key regulator of hepatic zonal gene expression and regulates several zonated metabolic pathways that may contribute to the development of fibrotic liver disease.

Indexed as

LiverLiver CirrhosisMetabolic Networks and PathwaysTranscription Factor 7-Like 2 ProteinAnimalsBile Acids and SaltsGene Expression RegulationHepatocytesMaleMiceMice, Inbred C57BLTranscription, GeneticBile Acids and SaltsTcf7l2 protein, mouseTranscription Factor 7-Like 2 Protein

Identifiers

PMID40210847
PMCPMC11986045

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.